A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease

A Multi-Center, Open Label, Single Arm, Multiple Dose Study to Assess the Pharmacokinetics of RO5072759 in Chinese Patients With CD20+ Malignant Disease

This multi-center, open-label, single-arm study will evaluate the pharmacokinetics and safety of obinutuzumab in participants with cluster of differentiation (CD) 20 positive (+) malignant disease. Participants will receive multiple doses of obinutuzumab. The anticipated time on study treatment is 24 weeks.

Inclusion Criteria:

• Diagnosis of CD20+ B-cell lymphoma or B-CLL
• Refractory/relapsed CLL, FL, and DLBCL
• At least 1 measurable lesion (greater than [>] 1.5 centimeters [cm] in its largest dimension) with the exception of CLL
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Life expectancy >6 months

Exclusion Criteria:

• Prior use of any investigational antibody therapy within 6 months of study start
• Prior use of any anti-cancer vaccine
• Prior administration of rituximab within 3 months of study start
• Prior administration of radioimmunotherapy 3 months prior to study entry
• Central nervous system lymphoma
• History of other malignancy
• Evidence of significant, uncontrolled concomitant disease
• Abnormal laboratory values
• Patients with progressive multifocalleukoencephalopathy (PML)
• Infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C